Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.

Author: Mikalar Voran
Country: Denmark
Language: English (Spanish)
Genre: Software
Published (Last): 4 January 2006
Pages: 115
PDF File Size: 10.84 Mb
ePub File Size: 6.77 Mb
ISBN: 902-6-54680-112-2
Downloads: 77917
Price: Free* [*Free Regsitration Required]
Uploader: Zulukree

The ineffectiveness arising from cash fow hedges which was recognised in Statement of Proft and Loss was not material.

The options vests evenly over a period of fve years from the date of grant. As per the Scheme, the share exchange ratio has been proposed as 0.

Annual Reports

Pending disposal of the annal, the management considers the impact as unascertainable. The amount is excluding interest and penalty, if any. Your Account is not yet activated Click here to receive activation mail once again. Dion Global Solutions Limited. Related party disclosures A] Names of rrport parties Related parties where control exists with whom no transactions have taken place during the current period or previous year: Clicking on the download link will add the report to your downloaded reports.

The Company has also issued redeemable non-convertible debentures which are listed for trading on the NSE in India. The same is expected to be resumed shortly.

Annual Reports | Sun Pharmaceutical Industries Ltd.

Ranbaxy gets approval from Japan for Dewas unit; stk up 24 Jul 09 Hence, the Company has become a potentially sick company in terms of the provisions of Sick Industrial Companies Special Provisions Reportt, and requisite compliances under this Act would be nanual by the Company. The following are the outstanding derivative contracts entered into by the Company: Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.


Nifty pares losses; Ranbaxy,Cipla lead 25 Sep 09 If the shares are listed on more than one stock exchange, then the stock exchange where there is highest trading volume on the said date shall be considered. Click here ajnual change registered Email ID.

Annual Reports & Presentations | Sun Pharmaceutical Industries Ltd.

Ranbaxy Laboratories is not traded in the last 30 days. The effective portion of such cash fow hedges was recorded as part of reserves and surplus within hedging reserve and re-classifed in the Statement of Proft and Loss in the period corresponding to the occurrence of the highly probable forecasted transactions.

It also includes a demand of Rs. The Company has not accepted the same and has fled its objections before the DRP.

Consequently, stock write off and other costs of Rs.

Annual Reports & Presentations

Thank you for your kind understanding. Options are granted at the discretion of the committee to selected employees depending upon certain criterion. Description cannot exceed characters. The amount above represents the difference payable. These derivatives ranbxxy not used for trading or speculation purposes.

Pursuant to the transaction, the Company has recorded a gain of Rs. The Company has challenged the order before the Hon”ble Income Tax Appellate Tribunal ITAT and pending disposal of the matter, the management considers the amount of tax liability as unascertainable. Daiichi Sankyo Propharma Co.


Please do reach out to us at contactus reportjunction. Nifty bounces over ; Bharti languishes 17 Feb 10 Options lapse, if they are not exercised prior to the expiry date, which reprt three months from the date of the vesting.

The options vests evenly over a period of three years from the date of grant.

RANBAXY Business Profile Ranbaxy Laboratories manufactures and markets pharmaceutical dosage forms for human health careanimal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents.

In calculating these provisions, the management has used the best information and estimates, presently available. ESOS provides annnual the grant price of options will be the latest available closing price on the stock exchange on which the shares of the Company are listed, prior to the date of the meeting of the Committee in which the options are granted.

The Annuxl expects to resume the operations shortly.

As at 31 Marchthere are no such derivative contracts which are ranbxxy as cash fow hedges. It is the largest exporter of bulk drugs and pharmaceutical dosag. We are attempting to resolve this funny technical issue! Further, the Company has deposited Rs.